ClinicalTrials.gg
RecruitingNCT07356674Updated May 4, 2026

Hemi-tibial Plateau Osteotomy Combined With Arthroscopic Repair for Medial Meniscus Posterior Root Tears in Varus Knees

An interventional study of Hemi-tibial plateau osteotomy combined with arthroscopic repair and High tibial osteotomy combined with arthroscopic repair in Knee Osteoarthristis and Meniscus Injury, sponsored by Eighth Affiliated Hospital, Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 35 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Eighth Affiliated Hospital, Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
35 Years to 75 Years
Sex
All
01

Study summary

This is a single-center clinical trial started by the study team. The goal is to compare two surgeries for people who have a varus knee alignment and a tear at the back attachment of the medial meniscus. Researchers want to learn how the newer bone-cut procedure with arthroscopic meniscus repair compares to the standard bone-cut procedure with arthroscopic meniscus repair. Researchers will also track safety and hospital-related costs.

Main questions the study aims to answer:

  • At 12 months after surgery, how does the improvement in knee function compare between the newer-surgery group and the standard-surgery group? The study will evaluate preliminary trends in clinical efficacy using the Lysholm knee function score.
  • Do the two groups differ in pain relief, imaging findings, meniscus healing, complications, and hospital stay and preliminary cost-effectiveness? The study plans to enroll about 20 participants at Sun Yat-sen University Eighth Affiliated Hospital (Shenzhen Futian). Participants will be assigned by chance, like drawing lots, in a one-to-one ratio. This is an pilot study with a PROBE (Prospective Randomized Open-label Blinded-Endpoint) design. While participants and surgeons will know which surgery is performed, the research assistant responsible for collecting patient-reported outcomes will be blinded to group allocation to minimize observer bias.

Study groups:

  • Experimental group: hemi-tibial plateau osteotomy plus arthroscopic meniscus repair.
  • Control group: high tibial osteotomy plus arthroscopic meniscus repair.

Who may join:

  • Age 35 to 65 years, with no restriction on sex;
  • Diagnosed with a medial meniscus posterior root tear;
  • Presence of varus knee deformity;
  • Imaging findings support the diagnosis (e.g., knee MRI);
  • Failure of conservative treatment: no meaningful improvement after more than 1 month of non-surgical management (e.g., rest, medication, or physical therapy);
  • Varus alignment angle less than 10 degrees;
  • The deformity is predominantly tibial in origin;
  • Knee radiographs do not show the most severe osteoarthritis (Kellgren-Lawrence grade other than IV).

Who cannot join:

  • A knee that is chronically "locked," meaning it cannot bend or straighten normally.
  • The most severe level of knee arthritis on knee X-ray.
  • Severe arthritis in the hip or ankle that could affect knee function testing.
  • Inflammatory or infectious conditions that can affect the knee, or abnormal inflammation blood tests that make participation unsafe.
  • Knee instability or poorly functioning prior ligament reconstruction, based on the study doctor's judgment.
  • Any prior surgery on the target knee, or on other joints of the same-side lower limb.
  • Serious heart, liver, or kidney disease, cancer, bleeding disorders, immune deficiency, or severe mental health conditions that make participation unsafe.
  • Body mass index of 30 or higher.
  • Pregnancy or breastfeeding, or not willing to use birth control during the study.
  • Participation in another clinical study within the past 3 months (except registry studies).
  • Any other reason the study doctor believes makes participation unsafe or not appropriate.

What participants will do:

  • Complete screening and baseline assessments within about 30 days before surgery and sign informed consent.
  • Receive the assigned surgery during the hospital stay.
  • Return for follow-up visits at 3 months, 6 months, and 12 months after surgery.
  • Complete knee function and symptom questionnaires and rate pain at each follow-up visit.
  • Have standing knee X-rays and full-length leg X-rays at 3, 6, and 12 months.
  • Have an MRI of the operated knee at 3, 6, and 12 months to assess meniscus healing and meniscus extrusion.

Outcomes:

  • Primary outcome: change from baseline to 12 months in the Lysholm knee function score.
  • Secondary outcomes: changes in the Lysholm score at 3 and 6 months; changes in the WOMAC knee arthritis symptom score at 3, 6, and 12 months; changes in pain rating on a standard pain scale at 3, 6, and 12 months; imaging measures and bone healing on X-rays; meniscus healing and extrusion on MRI; surgery time and blood loss; complications during and after surgery; length of hospital stay and hospital costs; and quality of life utility value from a standard health questionnaire.
02

Conditions studied

  • Knee Osteoarthristis
  • Meniscus Injury

Keywords

  • Hemi-tibial plateau osteotomy
  • High tibial osteotomy
  • Medial meniscus posterior root tears
  • Varus knees
03

In context

Lead sponsor

Eighth Affiliated Hospital, Sun Yat-sen University is the lead sponsor of 10 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 35 to 75 years, with no restriction on sex.
  • Clinical features suggestive of a medial meniscus posterior root tear, including at least one of the following symptoms: knee locking, clicking, or medial knee pain; and at least one of the following signs: medial joint line tenderness or a positive McMurray test.
  • Varus knee deformity with a varus angle of less than 10 degrees, with the deformity predominantly originating from the tibia (i.e., medial proximal tibial angle less than 87 degrees).
  • Knee MRI demonstrates a medial meniscus posterior root tear.
  • Knee radiographs show narrowing of the medial joint space, and Kellgren-Lawrence grade less than IV.
  • Failure of conservative treatment (e.g., rest, medication, or physical therapy) for more than 1 month.
  • Willing to accept randomization and able to understand and sign the form.
  • For participants with bilateral deformity, the more severely deformed side will be selected as the operative (study) side.

Exclusion criteria

Exclusion Criteria:

  • Chronic knee locking (e.g., the participant cannot bend or fully straighten the knee).
  • Kellgren-Lawrence grade IV knee osteoarthritis.
  • Osteoarthritis or other conditions in other joints (e.g., hip or ankle) that may affect assessment of knee function.
  • Known inflammatory diseases or other conditions that may affect knee function, including but not limited to: diseases (e.g., rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus); crystal-induced arthritis (gout, pseudogout); secondary knee osteoarthritis due to trauma or other diseases; active knee joint infection or a history of knee joint infection; reactive arthritis; systemic cartilage disorders; systemic connective tissue diseases; metabolic bone disease; fracture (acute or subacute fracture within 6 months prior to the screening visit); osteonecrosis; or abnormal inflammatory markers (C-reactive protein or high-sensitivity C-reactive protein at least 2 times the , or erythrocyte sedimentation rate at least 3 times the upper limit of normal), if judged by the investigator to be unsuitable for participation.
  • Target-knee instability (including but not limited to post-traumatic or congenital laxity) or inadequate ligament reconstruction, as judged by the investigator.
  • Any prior surgery on the target knee or on other joints of the ipsilateral lower limb.
  • Serious cardiac disease; hepatic impairment ( or alanine aminotransferase at least 3 times the upper limit of normal, or total serum at least 1.5 times the upper limit of normal); renal impairment (serum creatinine at least 1.5 times the upper limit of normal); other musculoskeletal disorders; ; coagulation disorders; immunodeficiency; or psychiatric disorders, if judged by the investigator to be unsuitable for participation.
  • at least 30 kg/m².
  • Pregnant or breastfeeding women, or participants (including men and women) unwilling to use during the study period.
  • Participation in another clinical study within 3 months prior to enrollment (excluding registry studies).
  • Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Hemi-tibial plateau osteotomy combined with arthroscopic repair

    Procedure: Hemi-tibial plateau osteotomy combined with arthroscopic repair

  • Active comparator
    High tibial osteotomy combined with arthroscopic repair

    Procedure: High tibial osteotomy combined with arthroscopic repair

Interventions

  • ProcedureHemi-tibial plateau osteotomy combined with arthroscopic repair

    The intervention is hemi-tibial plateau osteotomy combined with arthroscopic repair of the medial meniscus posterior root (HTPO combined with arthroscopic repair). After anesthesia and supine positioning, the medial compartment is opened by releasing the distal attachment of the superficial medial collateral ligament. Under fluoroscopic guidance, an L-shaped osteotomy is performed with the horizontal cut approximately 3.0 cm below the tibial plateau, while preserving the articular surface continuity at the hinge area to protect the cartilage and meniscus. A controlled valgus force is then applied to gradually open the osteotomy gap, and the lower-limb alignment is corrected to the preplanned target and confirmed by fluoroscopy. Arthroscopic repair of the medial meniscus posterior root is subsequently performed. The distal attachment of the superficial medial collateral ligament is advanced proximally and fixed below the horizontal osteotomy line, and the osteotomy is stabilized with a

  • ProcedureHigh tibial osteotomy combined with arthroscopic repair

    The control intervention is high tibial osteotomy combined with arthroscopic repair of the medial meniscus posterior root (HTO combined with arthroscopic repair). After anesthesia and supine positioning, the high tibial osteotomy is performed under fluoroscopic guidance according to the preoperative plan. A controlled valgus force is gradually applied to open the osteotomy gap, and the lower-limb alignment is corrected to the preplanned target and confirmed by fluoroscopy. Arthroscopic evaluation is then performed, followed by arthroscopic repair of the medial meniscus posterior root. The osteotomy site is stabilized with a proximal medial tibial anatomic locking titanium plate, and final fluoroscopic confirmation of alignment and fixation stability is obtained before wound closure.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Lysholm Knee Score (12 months)

    Lysholm knee score will be assessed preoperatively (baseline) and at 12 months after surgery. The primary endpoint is the change from baseline to 12 months (12-month score minus baseline score). Higher scores indicate better knee function.

    Time frame: Baseline (preoperative) and 12 months after surgery

Secondary outcomes

  1. Change From Baseline in Lysholm Knee Score (3 and 6 Months)

    Lysholm knee score will be assessed at baseline (preoperative) and at 3 and 6 months after surgery. The outcome is change from baseline at each time point (score at follow-up minus baseline score). Higher scores indicate better knee function.

    Time frame: Baseline (preoperative), 3 months, and 6 months after surgery

  2. Change From Baseline in WOMAC Total Score (3, 6, and 12 Months)

    The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score will be assessed at baseline and at 3, 6, and 12 months after surgery. The outcome is change from baseline at each time point (follow-up minus baseline). WOMAC total score ranges from 0 to 96, with lower scores indicating better symptoms/function.

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

  3. Change From Baseline in Pain Score (VAS) (3, 6, and 12 Months)

    Pain will be assessed using a 10-cm visual analogue scale (VAS) at baseline and at 3, 6, and 12 months after surgery. The outcome is change from baseline at each time point (follow-up minus baseline). The VAS ranges from 0 (no pain) to 10 (worst pain).

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

  4. Change in Mechanical Axis Location on Tibial Plateau (%MA) on Full-Length Lower Limb Radiographs

    On bilateral standing full-length lower limb radiographs, the mechanical axis (MA) will be evaluated by the relative location where the mechanical axis crosses the tibial plateau, expressed as a percentage (%MA). The outcome is %MA at each time point and change from baseline.

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

Other outcomes

  1. Change in EQ-5D-5L Health Utility Value

    Health-related quality of life will be assessed using the EQ-5D-5L questionnaire and converted to a health utility value using the China EQ-5D-5L value set. The outcome is the utility value at each time point and change from baseline (follow-up minus baseline).

    Time frame: Baseline (screening/preoperative), 0-7 days after surgery, 3 months, 6 months, and 12 months after surgery

  2. Quality-Adjusted Life Years (QALYs) Over 12 Months

    QALYs will be calculated over the 12-month follow-up period using EQ-5D-5L utility values collected at scheduled visits (area-under-the-curve approach). The outcome is total QALYs accrued from baseline to 12 months.

    Time frame: Baseline to 12 months after surgery

  3. Change in Kellgren-Lawrence Grade on Knee Radiographs

    Kellgren-Lawrence (K-L) grade will be assessed on knee radiographs at each time point to evaluate radiographic severity of knee osteoarthritis (grades 0-IV). The outcome is K-L grade at each time point.

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

  4. Bone Healing Grade at the Osteotomy Site (Modified Van Hemert System)

    Bone healing at the osteotomy site will be graded using a modified Van Hemert system on radiographs. Grades range from 1 to 5, where higher grades indicate more bridging callus and better healing (grade 5 indicates complete bridging). The outcome is healing grade at each time point.

    Time frame: 0-7 days after surgery, 3 months, 6 months, and 12 months after surgery

  5. Medial Meniscus Healing Status on MRI

    Medial meniscus posterior root healing will be assessed on MRI and categorized as complete healing, partial healing, or non-healing. Complete healing is defined as continuity of the repaired root seen on all three MRI planes (sagittal, coronal, and axial). Partial healing indicates loss of continuity in any one plane, and non-healing indicates no continuity in any plane. The outcome includes healing category and the proportion of participants in each category at each time point.

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

  6. Change in Medial Meniscus Extrusion Distance on MRI

    Medial meniscus extrusion will be measured on MRI as the distance between the outer edge of the medial meniscus and the edge of the medial tibial plateau on a standardized reference line. Outcomes include extrusion distance at each time point and change from baseline.

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

  7. Surgery-Related Outcomes, Complications, and Hospital Resource Use

    Surgery-related outcomes will include operative time and intraoperative blood loss. Safety outcomes will include intraoperative and postoperative complications (e.g., common peroneal nerve injury, deep vein thrombosis, infection, implant failure, delayed union, or nonunion). Hospital resource use will include length of hospital stay and hospitalization costs. Outcomes will be recorded during the perioperative period and through 12 months after surgery.

    Time frame: 0-7 days after surgery; 3 months, 6 months, and 12 months after surgery (complications assessed through 12 months)

  8. Change in Joint Line Convergence Angle (JLCA) on Standing Knee Radiographs

    JLCA will be measured on standing anteroposterior knee radiographs. The outcome is JLCA (degrees) at each time point and change from baseline (follow-up minus baseline).

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

  9. Change in Medial Joint Space Width (JS) on Standing Knee Radiographs

    Medial joint space width will be measured on standing anteroposterior knee radiographs. The outcome is joint space width (e.g., mm) at each time point and change from baseline (follow-up minus baseline).

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

  10. Change in Posterior Proximal Tibial Angle (PPTA) on Knee Radiographs

    PPTA will be measured on knee radiographs. The outcome is PPTA (degrees) at each time point and change from baseline (follow-up minus baseline).

    Time frame: Baseline (preoperative), 3 months, 6 months, and 12 months after surgery

  11. Change in Posterior Tibial Slope (PTS) on Lateral Knee Radiographs

    Posterior tibial slope will be measured on lateral knee radiographs. The outcome is PTS (degrees) at each time point and change from baseline (follow-up minus baseline).

    Time frame: Posterior tibial slope will be measured on lateral knee radiographs. The outcome is PTS (degrees) at each time point and change from baseline (follow-up minus baseline).

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Jan 21, 2026
StartActual
Mar 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07356674
Lead sponsor
Eighth Affiliated Hospital, Sun Yat-sen University
Responsible party
Mengjun Ma (Associate Chief Physician, Department of Orthopaedics, Eighth Affiliated Hospital, Sun Yat-sen University) — Principal investigator
First posted
Jan 21, 2026
Start date
Mar 1, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 4, 2026

Study contacts

Hanting Yi
Contact
yiht6@mail2.sysu.edu.cn
852-52091055

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion